Drug use in sub-Saharan Africa: quality in processes—safety in use

F Smith

Drug use in developing countries, which has often been described as “irrational”, is influenced by a wide range of factors. Interventions to promote safe and appropriate drug use must be delivered in the context of local services and settings.

Many researchers in developing countries have described drug use as “irrational”, documenting cases of ineffective, unsuitable, sub-optimal or unsafe prescribing, supply and/or consumption of pharmaceutical products. Drug use in these countries is influenced by many factors: health and drugs policy determines the legal framework for drug use and its regulation; the organisation and processes of healthcare provision affect access to professionals and drug therapy; and there are commonly big differences in the availability of drugs and services between regions (notably urban and rural areas). Provision and uptake of care are limited by financial constraints on the part of governments and individuals. Problems of access to objective product information, the role of the pharmaceutical industry in production and marketing, the prevalence of counterfeit products, and the difficulties of regulating professional practice and product quality are well recognised.

In sub-Saharan Africa traditional and western medical practices commonly operate side by side: drugs are used in the context of local health beliefs, cultural traditions, and individuals’ perspectives and preferences regarding the appropriateness of different courses of action and drug use.

Interventions to promote safe and appropriate drug use are seen as a vital response to the health problems of developing countries. In 1981 the World Health Organisation set up its Action Programme on Essential Drugs to provide operational support and guidance to developing countries in the establishment of national drugs policies. Over 80% of African countries now have national drugs programmes which initially focused on ensuring wider access to essential drugs. However, measures to improve drug use may be conceived at different levels and focus on any of a broad range of issues, from policy and regulation at a governmental level to prescribing practices and adherence rates at a practitioner/client level.

It is widely recognised, in industrialised as well as developing countries, that adherence to recommended medication regimens is often poor, potentially resulting in treatment failure. Boonstra and colleagues1 in this issue of QSHC show how the quality in the processes of care—in this case, dispensing procedures and labelling of medicines—affects patient knowledge which is seen as a prerequisite for adherence to medication. In the measurement of patient knowledge of medication researchers generally focus on the name and purpose of the medication, the dose, frequency of dosing, duration of treatment, and sometimes side effects2 because these elements are viewed as essential for safe and appropriate use. Labelling that is both correct and includes the relevant dosage information is also believed to be important. Researchers are generally aware of the tenuous relationship between knowledge and medication-taking behaviour. It is acknowledged that adherence is influenced by many factors including access to care, affordability of medication, and information and beliefs regarding the need for treatment. However, a recent study in public health facilities in Ghana3 demonstrated a link between improved patient information and labelling and adherence rates.

The value of trained staff to the quality of the dispensing process is shown by Boonstra et al.4 In many developing countries the more highly qualified professionals tend to be concentrated in the urban areas—for example, 837 of the 964 pharmacies in Ghana are in and around Accra and Kumasi, the country’s two largest cities.5 To obtain data representative of the different locations, Boonstra et al selected study sites that would reflect interregional differences in service provision. A more equitable distribution of trained staff across the country may be contingent on wider socioeconomic development, infrastructure, and amenities. However, Boonstra et al concluded that some training, even if limited, may lead to improvements in the quality of the prescribing and dispensing process and consequent outcomes regarding the safety and appropriateness of medication use.

Many researchers, especially social scientists, have described patterns of drug use in the context of local cultural traditions and health beliefs. Practices that may appear to western practitioners as irrational have sometimes been explained in terms of local perspectives and experiences of drug use. In terms of promoting more rational drug use, many of these researchers have highlighted the importance of ensuring that the design and delivery of health programmes take into account the health beliefs and perspectives of local people. In many African countries public sector health personnel (sometimes in comparison with private practitioners) have been perceived as relatively unapproachable, disinclined to spend time with clients, and unwilling to respond to their concerns and views. In their study in Botswana the “barefoot doctors”6 describe how family welfare educators—who were often members of the communities in which they worked—were sometimes referred to Botswana’s “barefoot doctors”. As such, they enjoyed the trust of their local communities despite their limited training, and thus could play a valuable healthcare role.

Boonstra et al also reported a mean dispensing counselling time of 25 seconds. As they point out, if this time was increased it would provide greater opportunity for providing relevant information and for ensuring that this was understood. As a person’s concerns and views regarding drug use are known to influence adherence, increased emphasis on the counselling component of the dispensing process would enable these perspectives to be identified and addressed.

In many developing countries public health facilities are only one of many sources of drugs. Local pharmacies, drug stores, chemical sellers, and drug peddlers are important suppliers of pharmaceuticals in many communities. However, despite the widely acknowledged pluralism in healthcare provision, interventions (and their assessment) to improve the quality and safety of drug use have generally focused on public sector care. Exclusion of private practitioners from programmes to improve drug use limits their potential coverage and effectiveness, and may also represent a lost opportunity on the part of health policy makers in achieving national or local health policy objectives.
To promote improvements in the quality of health care which meet specific policy objectives, indicators should be continually reviewed. Boonstra et al identify simple patient knowledge and labelling scores which, as measures of the quality of the processes of care (in this case prescribing and dispensing), would be expected to reflect improved outcomes—namely, safer and appropriate drug use.

Qual Saf Health Care 2003;12:164–165

Authors’ affiliations
F Smith, Reader in Pharmacy Practice, School of Pharmacy, University of London, 29–39 Brunswick Square, London WC1N 1AX, UK; felicity.smith@ucl.ac.uk

REFERENCES

Adverse drug events

Adverse drug events: what’s the truth?
B Dean

Reasons for the wide range in reported adverse drug event rates include discrepancies in the definitions and data collection methods used. Great care must be taken when interpreting the results of studies of adverse drug events and other types of medical harm, and standardised methods and definitions are needed to compare adverse drug event rates.

You don’t have to look very far to find that the number of patients being harmed by medication is perceived to be a problem. Nearly every medical, pharmaceutical, and nursing journal frequently publishes articles to this effect. Key documents on medical error—drawing particular attention to the harm caused by medication—have been produced by the US Institute of Medicine and by both the Department of Health and the Audit Commission in the UK. Add to this the widespread coverage at professional conferences and in the media, and it is clear that adverse drug events (ADEs) appear to represent an epidemic.

What is less clear is how often ADEs actually occur. An enormous range of figures have been reported in the literature and are cited regularly—suggesting that ADEs occur in anything from 0.7% to 6.5% of hospital inpatients.1,2 In this issue of QSHC a further paper is published in which 720 ADEs were identified in 2837 inpatients (25%).3 So why this range of figures and, perhaps more pertinently, does this mean some institutions are safer than others?

Before considering this question it is important to pause for a minute to think about what is being measured, as the definitions and terminology used in the area of iatrogenic harm are notoriously confusing. ADEs refer to instances where patients are unintentionally harmed as a result of drug use. This includes harm that occurs due to either an adverse drug reaction or a medication error.4 Medication errors are generally considered to be preventable whereas adverse drug reactions (or side effects, in common parlance) are less so. Medication errors may or may not result in ADEs, and a separate but overlapping body of literature examines these in more detail.

Returning to our question of why such a range of ADE rates has been reported, there are three possible reasons. The first is that, within the general definition of an ADE given above, there is wide discrepancy in what is considered to constitute “harm”. For example, in the Harvard Medical Practice study, one of the most well known studies of iatrogenic injury, harm was defined as “measurable disability at discharge or increased length of stay due to the event”. This study therefore included only events that resulted in more serious levels of harm. The US based ADE Prevention Study Group did not define the level of harm they included, but suggest that “all” ADEs were studied; only 8% of the ADEs they identified met the definition used in the Harvard study. The paper by Rozich et al also suggests that any degree of harm was included.

The second possible reason is that a wide range of data collection methods have been used. The Harvard study and similar Australian and UK studies5 were based on a retrospective review of medical notes. There are many reasons why ADEs may not be documented in the medical notes, and this method may therefore lead to underreporting. The ADE Prevention Study Group instead used targeted self-reporting and daily medical record review, an approach which is likely to identify more ADEs than a retrospective review of medical notes but may still miss those that are not recognised as such or otherwise neither reported nor documented. Another approach is to develop a computer based system to prospectively screen for ADEs based on “triggers”—that is, results of laboratory tests or orders for medication that may indicate that an ADE has occurred. The medical notes for those patients with positive triggers can then be examined in more detail. Using this method, Classen et al found an ADE in 1.7% of patients. The method described by Rozich et al is based on this approach, but involves manually screening for triggers instead of requiring an ADE screening programme to be integrated with computerised prescribing and results reporting systems. These methods may be useful to find evidence of ADEs that are neither reported nor documented clearly in the medical notes, but any ADEs that do not result in a trigger will be missed.

The third reason why there may be differences in reported ADE rates is that there may be differences in the underlying ADE rates in the different institutions. However, without a standardised method for identifying ADEs we do not know the extent to which this is the case. The data of Rozich et al suggest that the differences are not great, with a range of 2.47–4.81 ADEs per 1000 doses reported across the 86 hospitals studied (mean 2.68).

These issues clearly demonstrate two points: firstly, that great care needs to be taken when interpreting the results of studies of ADEs and other types of medical harm; and, secondly, that we desperately need standardised methods and definitions to compare ADE rates in different institutions and in the same institution following large scale changes.
Nursing home quality

Rights, risks, and autonomy: a new interpretation of falls in nursing homes

A Ryan

Achieving the balance between safety and the right of nursing home residents to dignity, choice and self-determination is a challenging issue.

Families caring for older people worry particularly about the safety of their vulnerable relatives. It is often such concern about safety that prompts the final decision to seek nursing home care. In many cases this follows a lengthy period of care in the community where the physical safety of older people may be compromised to respect their right to self-determination and choice. For many families, underpinning the decision to opt for institutional care is the belief that at least their relative will now be safe.

With demographic trends predicting an increase in the number of older people and a reduction in the number of carers, it is likely that admission to nursing homes will continue to increase. In light of this, initiatives such as the National Service Framework for Older People and the “Essence of Care” benchmarking project are setting new standards of care for older people. In his paper in this issue of *QSHC*, Kapp highlights many issues that people with an interest in the health and social care of older people will readily appreciate. Few will disagree that the issue of safety is as complex as it is poorly defined. While there can only be a consensus that care homes should provide safety and security, the issue of what exactly constitutes a safe environment warrants further exploration. Clearly, there are many instances where the safety of nursing home residents is compromised through adverse drug reactions, injurious falls, and pressure ulcers. However, it would be remiss to suggest that these problems are unique to the nursing home sector when, in fact, they clearly occur in other settings also.

Protecting the right of vulnerable older people is an issue of international importance. In the UK, care homes are closely monitored by a system of scrutiny that includes a number of visits by the Registration and Inspection Unit. Interestingly, the care of older people in acute settings is not subject to this degree of independent scrutiny. One cannot but speculate on the findings that might emerge if this were, in fact, the case. Put simply, any initiative aimed at enhancing the quality of care for older people must transcend specific locations and reflect an underlying philosophy that recognises the need to balance rights with risks.

One effect of an increasingly litigious society is to encourage staff to restrict the activities of the older people in their care. However, this surely begs the question as to the cost to the overall well being of the older person at which this is to be achieved. Safety will always be a key issue in nursing home care, but questions need to be asked about exactly who is being safeguarded. Is it the resident? If so, is it his/her right to dignity, choice and self-determination even in the face of real or perceived physical risk? Is it the nursing home owners whose determination to avoid negative publicity and litigation outwits their determination to reduce them. As well as being practical for routine use, such a method would have to be tested in terms of its validity and reliability. The extent to which a method could be used in countries outside the one in which it was developed would also require careful consideration; prescribing practice, laboratory reference ranges, and drug names can differ immensely. These issues represent major challenges for those wanting to show a reduction in the number of patients being harmed by drug use.


**Author’s affiliation**
B Dean, Director, Academic Pharmacy Unit, Hammersmith Hospitals NHS Trust and the School of Pharmacy, University of London, London W12 0HS, UK. bdean@hhnt.org

**REFERENCES**

**COMMENTS**

It would be naïve to underestimate the real risks in adopting such a position, and cynics are justified in believing that some institutions may abuse a liberal approach. However, if we are serious in our effort to address residents’ autonomy, a
triartite approach involving residents, relatives, and nursing home staff will have to be the norm. This is wholly consistent with the concept of “relationship-centred” care⁵, which proposes that the enhancement of relationships should be at the centre of education and practice. Nursing home staff who show a genuine willingness to respect residents’ autonomy cannot continually live in fear of litigation. Similarly, residents and relatives must appreciate the fine balance between rights and risks that will continuously have to be negotiated in a client-centred environment.

Fostering the innovation and creativity that is required to address the issue of resident safety in such a broad context is a huge challenge. In an ever increasing client-centred environment, it will continue to gain momentum and, as the older people of the future, we would be well advised to take note!

Qual Saf Health Care 2003;12:166–167

Author’s affiliation
A Ryan, School of Nursing, University of Ulster, Coleraine, Northern Ireland, UK; aa.ryan@ulster.ac.uk

REFERENCES

Clinical Evidence—Call for contributors

Clinical Evidence is a regularly updated evidence based journal available worldwide both as a paper version and on the internet. Clinical Evidence needs to recruit a number of new contributors. Contributors are health care professionals or epidemiologists with experience in evidence based medicine and the ability to write in a concise and structured way.

Currently, we are interested in finding contributors with an interest in the following clinical areas:

Altitude sickness; Autism; Basal cell carcinoma; Breast feeding; Carbon monoxide poisoning; Cervical cancer; Cystic fibrosis; Eclectic pregnancy; Grief/bereavement; Halitosis; Hodgkins disease; Infectious mononucleosis (glandular fever); Kidney stones; Malignant melanoma (metastatic); Mesothelioma; Myeloma; Ovarian cyst; Pancreatitis (acute); Pancreatitis (chronic); Polymyalgia rheumatica; Post-partum haemorrhage; Pulmonary embolism; Recurrent miscarriage; Repetitive strain injury; Scoliosis; Seasonal affective disorder; Squint; Systemic lupus erythematosus; Testicular cancer; Varicocoele; Viral meningitis; Vitiligo

However, we are always looking for others, so do not let this list discourage you.

Being a contributor involves:

• Appraising the results of literature searches (performed by our Information Specialists) to identify high quality evidence for inclusion in the journal.
• Writing to a highly structured template (about 2000–3000 words), using evidence from selected studies, within 6–8 weeks of receiving the literature search results.
• Working with Clinical Evidence Editors to ensure that the text meets rigorous epidemiological and style standards.
• Updating the text every eight months to incorporate new evidence.
• Expanding the topic to include new questions once every 12–18 months.

If you would like to become a contributor for Clinical Evidence or require more information about what this involves please send your contact details and a copy of your CV, clearly stating the clinical area you are interested in, to Claire Folkes (cfolkes@bmjgroup.com).

Call for peer reviewers

Clinical Evidence also needs to recruit a number of new peer reviewers specifically with an interest in the clinical areas stated above, and also others related to general practice. Peer reviewers are health care professionals or epidemiologists with experience in evidence based medicine. As a peer reviewer you would be asked for your views on the clinical relevance, validity, and accessibility of specific topics within the journal, and their usefulness to the intended audience (international generalists and health care professionals, possibly with limited statistical knowledge). Topics are usually 2000–3000 words in length and we would ask you to review between 2–5 topics per year. The peer review process takes place throughout the year, and our turnaround time for each review is ideally 10–14 days.

If you are interested in becoming a peer reviewer for Clinical Evidence, please complete the peer review questionnaire at www.clinicevidence.com or contact Claire Folkes (cfolkes@bmjgroup.com).

4 Kapp MB. “At least Mom will be safe there”: the role of resident safety in nursing home quality. Qual Saf Health Care 2003;12:201–204.